L. Entreprises-du-médicament, E. Le, H. Schirm, T. Tobi, I. De-vries et al., Evidence of harm from off-label or unlicensed medicines in children [En ligne] Disponible sur: http://www.ema.europa.eu/docs/en_GB/document_library/Other De Jong-van den Berg, « Lack of appropriate formulations of medicines for children in the community [6] United Nations, « Convention on the Rights of the Child », UNICEF, nov Droit civil: Introduction au droit, personnes, famille, personnes protégées, biens, obligations, sûretés La naissance de l'intelligence de l'enfant, 9ème édition « Clinical investigation of medicinal products in the pediatric population Sonies, et C. Macedonia, « Emergence of oropharyngeal, laryngeal and swallowing activity in the developing fetal upper aerodigestive tract: an ultrasound evaluation Debotton et A. Dahan, « A mechanistic approach to understanding oral drug absorption in pediatrics: an overview of fundamentals Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups, Disponible sur 1238?1244, déc. 1962. [4] European Medicines AgencyWC500004021.pdf. [Consulté le: 08-févr-2015]. [5] Introduction. Neuchâtel: Delachaux et Niestlé, 1977. [9] International Conference on Harmonisation Pediatric Development: Physiology. Enzymes, Drug Metabolism, Pharmacokinetics and Pharmacodynamics Pediatric formulations: a roadmap, D. Bar- Shalom and K. Rose. EMC -Gastro-Entérologie, pp.1-2015, 1938.

J. , E. S. Abdel-rahman, and «. , Single dose pharmacokinetics of pleconaril in neonates, Pediatr. Infect. Dis. J, vol.1916, issue.9, 2000.

E. Lebenthal, P. C. Lee17-]-k, S. S. Nibha, . Pancholi-]-v, G. Jannin et al., An overview on: Sublingual route for systemic drug delivery » Oral transmucosal drug delivery for pediatric use Tuleu, « Rectal route in the 21st Century to treat children », Adv « Intravenous drug delivery in neonates: lessons learnt « A literature review on flow-rate variability in neonatal IV therapy, Development of Functional Response in Human Exocrine Pancreas Intramuscular Injections in Children 944?948, déc Vaccine Administration Guidelines. » US Department of Health and Human Serves, 2014. [24] W. A. Engle, « Intraosseous Access for Administration of Medications in Neonates 161?168, mars 2006. [25] L. D. Mastrandrea et T. Quattrin, « Clinical evaluation of inhaled insulin 9?10, p. 1061?1075, oct. 2006. [26] J. M. Couriel et F. Child, « Applied physiology: lung function testing in children », Curr. Paediatr. Topical and Transdermal Pediatric formulation: a roadmap, pp.913-923, 1980.

E. S. Supornsilchai, . Wananukul, A. Exogenous, G. Fortuna, A. Alves et al., Falcão, « Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules », Eur « Direct measurement of ear canal volume in a pediatric population: Can we explain its individual variation in terms of age and body weight?, 51?57, mars 1996. [32] H. Noh et D.-H. Lee, pp.658-662, 2003.

R. J. Bowman, J. Cope, K. K. Nischal, M. Esmaeelpour, P. O. Watts et al., Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan??) in children, Tear Film Volume and Protein Analysis in Full-term Newborn Infants », Cornea 400?404, avr. 2011. [35] J.-P. Labaune, Pharmacocinétique!: principes fondamentaux, pp.24-26, 1984.
DOI : 10.1067/mpa.2001.117571

J. Devissaguet, ». Peut, F. J. Httpwwwem-premiumcomdatarevues0003450900590004219, E. Fjalstad, J. Laukli et al., Thakker, « A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children Klingenberg, « High-dose gentamicin in newborn infants: is it safe? Sebire, « Reference ranges for organ weights of infants at autopsy: results of >1,000 consecutive cases from a single centre, 1171?1182, déc 320S?329S, mai 2014. [39] Barrier Mechanisms in the Developing Brain févr. 2012. [43] B. Engelhardt et S. Liebner, « Novel insights into the development and maintenance of the blood?brain barrier 687?699, janv. 2014. [44] L. Notarianni, « Plasma Protein Binding of Drugs in Pregnancy and in Neonates, pp.93-113, 1990.

M. S. Kauffman, R. Benedetti, M. M. Whomsley, R. Benedetti, E. L. Whomsley et al., Canning, « Drug metabolism in the paediatric population and in the elderly « Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations, Developmental Pharmacology ? Drug Disposition, Action, and Therapy in Infants and Children 447?471, sept. 2005. [48] G. D. Anderson, « Developmental Pharmacokinetics, pp.208-213, 2003.

R. N. Hines, ». , I. J. Pharm, F. Glowacki, A. Lionet et al., Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients « Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood », Br « The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification, Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release 585?591, nov Pharmacokinetics of imipenem-cilastatin in neonates. » Questions and answers on Tienam and associated names (imipenem/cilastatin for infusion 500 mg/500 mg), pp.431-435, 1985.

E. G. Badoual, ]. Olive57, E. Pariente-khayat, D. Rey, F. Gendrel et al., Pons, « Isoniazid acetylation metabolic ratio during maturation in children, Caffeine Acetylator Phenotyping during Maturation in Infants, pp.492-495, 1991.

E. Krynetski, W. E. Evans, B. Pettersson, S. Almer, F. Albertioni et al., Drug methylation in cancer therapy: lessons from the TPMT polymorphism, Acetylation Polymorphism: Prevalence of Slow Acetylators Does Not Differ between Atopic Dermatitis Patients and Healthy Subjects Differences Between Children and Adults in Thiopurine Methyltransferase Activity and Metabolite Formation During Thiopurine Therapy: Possible Role of Concomitant Methotrexate Glucuronidation in Humans », pp.386-392, 1999.
DOI : 10.7326/0003-4819-126-8-199704150-00003

A. Mulhall, J. De-louvois, and E. R. Hurley, Chloramphenicol toxicity in neonates: its incidence and prevention., 1424?1427, nov, 1983.
DOI : 10.1136/bmj.287.6403.1424

A. Kocarek and M. Runge-morris, « Developmental Expression of Aryl, Estrogen, and Hydroxysteroid Sulfotransferases in Pre-and Postnatal Human Liver, Vest et R. Rossier, « Detoxification in the newborn: the ability of the newborn infant to form conjugates with glucuronic acid, glycine, actetate and glutathione », pp.1310-1317, 2006.

. Acad, . V. Sci65-]-e, D. G. Capparelli, R. N. Mccarver, ]. W. Hines67 et al., Pharmacokinetic considerations in the adolescent: Noncytochrome P450 metabolic pathways « The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms, « L'estimation du débit de filtration glomérulaire en 2012 : quelle valeur ajoutée pour la nouvelle équation CKD-EPI ? », Néphrologie Thérapeutique Ontogeny of drug elimination by the human kidney How to Estimate the Dose to Be Given for the First Time to Pediatric Patients Pediatric Formulations. [71] Organisation Mondiale de la Santé, « OMS | Poids-pour-l'âge, pp.183-198, 1963.

. Disponible-sur, Consulté le: 01- févr-2015]. [72] U.S. Food and Drug Administration, « Pediatric Science and Research Activities », 2015. [En ligne]. Disponible sur: http://www.fda.gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch, History of the Paediatric initiatives, 2007.

C. Back, A. , and «. Qu, « Les essais cliniques pédiatriques': de la théorie à la réalité du terrain, 2012.

G. Disponible-sur-renaud, B. Durrieu, S. Escourrou, and J. Oustric, Consulté le: 15-févr-2015]. [79] ANSM, « Résumé du Rapport Périodique de Synthèse N°2 Orphan Europe Autorisation Temporaire d'Utilisation de Cohorte (ATUc) Cystadrops® 0.55% Collyre en solution the survey of all paediatric uses of medicinal products in Europe, L'usage compassionnel en Europe et en France. Illustration': le crizotinib en ATU Disponible sur, 2010.

E. M. Montastruc and . Lapeyre-mestre, Food and Drug Administration, « Federal Food and Drugs Act of 1906 -The Wiley Act », Legislation _ Federal Food and Drugs Act of 1906 Disponible sur: http://www.fda.gov/RegulatoryInformation/Legislation/ucm148690.htm. [Consulté le: 12- avr-2015]. [84] Congrès des Etats-Unis d'Amérique, « Food and Drug Administration Modernization Act of 1997. » City of Washington, 1997. [85] Congrès des Etats-Unis d'Amérique, « Best Pharmaceuticals for Children Act [En ligne] Disponible sur: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDC Act/SignificantAmendmentstotheFDCAct/ucm148011.htm. [Consulté le: 12-avr-2015]. [86] Congrès des Etats-Unis d'Amérique, « Pediatric Research Equity Act of, Off-Label Prescribing in Pediatric Outpatients Are the Kids Alright? | The Scientist Magazine® », 2012. [89] Conseil de la Communauté Européenne, « Directive 65 Disponible sur, pp.26-196531965, 1906.

. Disponible-sur, Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies. » 2014. [94] European Medicines Agency, « Decision Class Waiver on conditions -granting, review, revocation. » 2011. [95] European Medicines Agency, « SOP3207 -Handling of applications for paediatric investigation plan and or waiver from presubmission to PDCO [96] European Medicines Agency, « Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards, 98] European Medicines Agency, « Application guidance -Standard paediatric investigation plans Disponible sur99] European Medicines Agency, « Questions and answers on the paediatric use marketing authorisation, 2009.

A. European-medicines, Better Medicines for Children: From concept to reality, Progress report on the paediatric regulation (EC) N°1901, 2006.

A. R. Kreeftmeijer-vegter, A. De-boer, R. H. Van-der-vlugt-meijer, and E. P. De-vries, The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children, Orphanet Journal of Rare Diseases, vol.92, issue.L18, pp.120-120, 2014.
DOI : 10.1002/bdrb.20328

A. European-medicines, « Presse realease of a second positive opinion for a PUMA, 2014.

G. Winzenburg, More than 5 years of European Paediatric Regulation: Statistics and industrial experience, Initiat. EuPFI 5th Annu. Conf. 2013, pp.260-262, 2014.
DOI : 10.1016/j.ijpharm.2014.03.058

A. European-medicines, « Draft guideline on pharmaceutical development of medicines for paediatric use, 2011.

N. Spomer, V. Klingmann, I. Stoltenberg, C. Lerch, T. Meissner et al., Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study, Archives of Disease in Childhood, vol.97, issue.3, pp.283-286, 2012.
DOI : 10.1136/archdischild-2011-300958

R. Venables, H. Batchelor, J. Hodson, H. Stirling, and E. J. Marriott, Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population », Int, J. Pharm, vol.480, issue.1?2, pp.55-62, 2015.

E. C. Flanagan and . Tuleu, « Patient-Centred Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations, Drugs, vol.74, issue.16, pp.1871-1889, 2014.

R. G. Strickley, Q. Iwata, S. Wu, and T. C. Dahl, Pediatric Drugs-A Review of Commercially Available Oral Formulations, Journal of Pharmaceutical Sciences, vol.97, issue.5, pp.1731-1774, 2008.
DOI : 10.1002/jps.21101

«. Grip and . Global, Research in Paediatrics (GRiP) -paediatric clinical pharmacology studies. » [En ligne] Disponible sur: http://www.grip-network.org/index, Consulté le, pp.5-2015

W. W. Walton, « An Evaluation of the Poison Prevention Packaging Act, Pediatrics, vol.69, issue.3, pp.363-370, 1982.

G. Rodgers and «. , The Safety Effects of Child-Resistant Packaging for Oral Prescription Drugs, JAMA, vol.275, issue.21, pp.1661-1665, 1996.
DOI : 10.1001/jama.1996.03530450051032

H. S. Yin, B. P. Dreyer, D. C. Ugboaja, D. C. Sanchez, I. M. Paul et al., Unit of Measurement Used and Parent Medication Dosing Errors, PEDIATRICS, vol.134, issue.2, pp.354-361, 2014.
DOI : 10.1542/peds.2014-0395

A. and «. Pipettes, administration des solutions buvables': attention aux erreurs -Point d'Information », 2013. [En ligne] Disponible sur: http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Pipettes-et-autres- dispositifs-d-administration-des-solutions-buvables-attention-aux-erreurs-Point-d-Information, pp.5-2015

J. A. Mennella, A. C. Spector, D. R. Reed, and S. E. Coldwell, The Bad Taste of Medicines: Overview of Basic Research on Bitter Taste, The Bad Taste of Medicines: Overview of Basic Research on Bitter Taste, pp.1225-1246, 2013.
DOI : 10.1016/j.clinthera.2013.06.007

A. Shahiwala, Formulation approaches in enhancement of patient compliance to oral drug therapy, Expert Opinion on Drug Delivery, vol.115, issue.4, pp.1521-1529, 2011.
DOI : 10.1016/S0168-3659(99)00222-9

R. Cohen, F. De-la-rocque, A. Lécuyer, C. Wollner, and M. Bodin, Study of the acceptability of antibiotic syrups, suspensions, and oral solutions prescribed to pediatric outpatients, European Journal of Pediatrics, vol.115, issue.Suppl 1, pp.851-857, 2009.
DOI : 10.3928/0090-4481-19961101-06

L. Brondel, A. Jacquin, S. Meillon, and E. L. Pénicaud, Le go??t??: physiologie, r??les et dysfonctionnements, Nutrition Clinique et M??tabolisme, vol.27, issue.3, pp.123-133, 2013.
DOI : 10.1016/j.nupar.2013.06.002

M. Faculté-de-médecine-pierre and «. Curie-de-paris, Histologie : organes, systèmes et appareils. » [En ligne] Disponible sur, pp.6-2015

P. Moller, D. Bar-shalom, and K. Rose, Orosensory Perception, Pediatric formulations: a roadmap, pp.117-118, 2014.
DOI : 10.1007/978-1-4899-8011-3_8

J. A. Mennella and N. K. Bobowski, The sweetness and bitterness of childhood: Insights from basic research on taste preferences, Physiology & Behavior, vol.152
DOI : 10.1016/j.physbeh.2015.05.015

M. Pein, M. Preis, C. Eckert, and F. E. Kiene, « Taste-masking assessment of solid oral dosage forms?A critical review », Int, J. Pharm

M. Preis, L. Grother, P. Axe, and E. J. Breitkreutz, « In-vitro and in-vivo evaluation of taste-masked cetirizine hydrochloride formulated in oral lyophilisates », Int, J. Pharm, vol.491, issue.1?2, pp.8-16, 2015.

M. L. Angelilli, M. Toscani, D. M. Matsui, and M. J. Rieder, Palatability of Oral Antibiotics Among Children in an Urban Primary Care Center, Archives of Pediatrics & Adolescent Medicine, vol.154, issue.3, pp.267-270, 2000.
DOI : 10.1001/archpedi.154.3.267

J. Soto, Y. Sheng, J. F. Standing, M. O. Gul, and E. C. Tuleu, Development of a model for robust and exploratory analysis of the rodent brief-access taste aversion data, European Journal of Pharmaceutics and Biopharmaceutics, vol.91, pp.47-51
DOI : 10.1016/j.ejpb.2015.01.016

D. Clapham, D. Kirsanov, A. Legin, A. Rudnitskaya, and E. K. Saunders, Assessing taste without using humans: Rat brief access aversion model and electronic tongue, Better Med. Child. ? Eur. Paediatr. Formul. Initiat. EuPFI 3rd Annu. Conf, pp.137-139, 2012.
DOI : 10.1016/j.ijpharm.2012.05.056

R. S. Latha and P. K. Lakshmi, « Electronic tongue: An analytical gustatory tool, J

K. Woertz, C. Tissen, P. Kleinebudde, and E. J. Breitkreutz, A comparative study on two electronic tongues for pharmaceutical formulation development, Journal of Pharmaceutical and Biomedical Analysis, vol.55, issue.2, pp.272-281, 2011.
DOI : 10.1016/j.jpba.2011.02.002

K. Woertz, C. Tissen, P. Kleinebudde, and E. J. Breitkreutz, Performance qualification of an electronic tongue based on ICH guideline Q2, Journal of Pharmaceutical and Biomedical Analysis, vol.51, issue.3, pp.497-506, 2010.
DOI : 10.1016/j.jpba.2009.09.029

K. Woertz, C. Tissen, P. Kleinebudde, and E. J. Breitkreutz, Taste sensing systems (electronic tongues) for pharmaceutical applications, International Journal of Pharmaceutics, vol.417, issue.1-2, pp.256-271, 2011.
DOI : 10.1016/j.ijpharm.2010.11.028

J. Walsh, A. Cram, K. Woertz, J. Breitkreutz, G. Winzenburg et al., Tuleu, « Playing hide and seek with poorly tasting paediatric medicines: Do not forget the excipients, Drug Deliv. Paediatr. Popul. Are We At, vol.73, pp.14-33, 2014.